ReviewJournal of translational medicine2026
Stromal cells contribute to progression, recurrence, and metastasis in oral squamous cell carcinoma: a call for therapy.
Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Observational
- An Integrative Bioinformatics Framework Prioritises a Gingival Mesenchymal Stem Cell Paracrine Apoptosis-ROS Axis in HPV-Negative Oral Squamous Cell Carcinoma: Preliminary Experimental Support and Repurposable-Drug Hypotheses.International journal of molecular sciences · 2026Article
- Genetics and Molecular Mechanisms in Oral Squamous Cell Carcinoma: A Narrative Review.Medicina (Kaunas, Lithuania) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundOral squamous cell carcinoma (OSCC) has a poor prognosis due to late-stage diagnosis, early metastasis, and resistance to treatment. OSCC is heavily influenced by its tumor microenvironment (TME), especially the stromal cell populations, which support tumor growth and contribute to recurrence and treatment resistance. Despite the tumor-stroma ratio being linked to disease progression, it is not yet part of standard staging. Moreover, it is not directly addressed by current treatments, including surgery, radiation, and chemotherapy. MAIN BODY: Among the diverse stromal components, specific cell types play distinct yet complementary roles. Pericytes regulate angiogenesis and vascular stability, while their dysfunction causes immature vessels and neovascularization. Anti-angiogenic therapy restores vascular integrity, increases pericyte coverage, and improves drug delivery. MSCs promote tumor progression through cytokine release, angiogenesis, and extracellular matrix remodeling, with their effects varying based on their origin. CAFs are the predominant non-immune cells in tumors, playing a critical role in tumor initiation, progression, and metastasis by remodeling the extracellular matrix, secreting cytokines, and promoting epithelial-mesenchymal transition. Endothelial cells facilitate metastasis by promoting angiogenesis, endothelial-to-mesenchymal transition, and immune evasion through VEGF, miRNAs, and Rho/YAP and TGF-β signaling, enhancing tumor growth, migration, and chemoresistance.
conclusionCollectively, stromal cells in OSCC, including pericytes, MSCs, CAFs, and endothelial cells, play a critical role in tumor progression, metastasis, and drug resistance, highlighting the potential for targeting these cells in future therapies to improve clinical outcomes and patient prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.